How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-b-raf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Anti-B-RAF — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-B-RAF (Anti-B-RAF) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: B-Raf inhibitor. Area: Oncology.

phase 2 B-Raf inhibitor B-Raf Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Anti-B-RAF (Anti-B-RAF) — Istituto Oncologico Veneto IRCCS. Anti-B-RAF drugs target and inhibit the B-Raf protein, which is often mutated in cancer cells.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Anti-B-RAF TARGET	Anti-B-RAF	Istituto Oncologico Veneto IRCCS	phase 2	B-Raf inhibitor	B-Raf
Tafinlar	dabrafenib	Novartis	marketed	Kinase Inhibitor	Serine/threonine-protein kinase B-raf	2013-01-01
Zelboraf	vemurafenib	Hoffmann La Roche	marketed	Kinase Inhibitor [EPC]	Serine/threonine-protein kinase B-raf	2011-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (B-Raf inhibitor class)

Istituto Oncologico Veneto IRCCS · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-B-RAF — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-b-raf. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing